ID: 203843 A Rare Case of Ibrutinib-Induced Polyneuropathy

Abstract

The B-cell-receptor (BCR) pathway, which includes Bruton’s-Tyrosine-Kinase (Btk) protein, regulates proliferation, differentiation, and apoptosis of B-cells. In B-cell malignancies such as chronic lymphocytic leukemia (CLL), aberrant BCR signaling plays critical role in pathogenesis of disease. Ibrutinab is irreversible Btk inhibitor that prevents downstream activation of the BCR pathway and subsequent proliferation of malignant B-cells. In this case report, patient with history of Ibrutinab use for several years for CLL treatment had rare adverse effect (AE) of Ibrutinib-inducted-polyneuropathy, which was only reported once in literature.